TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11161897

Group type: EXPERIMENTAL
Intervention: Selective decontamination of digestive tract (SDD)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: No intervention (non-SDD unit)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 61
Study: 9562504

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adjustment with risk factors (hypertension, myocardial infarction, factor VIIc, factor VIIIc, cholesterol, HDL cholesterol, smoking, diabetes mellitus)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Adjustment with fibrinogen and indicators of carotid atherosclerosis (intima-media wall thickness, plaques)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Correction with local ratings of cortical atrophy
Number of subjects: 60
Study: 7836964

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CHLP, 50 mg, i.m.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (SD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (18 healthy volunteers)
Number of subjects: 41
Study: 3354865

Group type: EXPERIMENTAL
Intervention: Nalbuphine hydrochloride 0.2 mg/kg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meperidine 0.5 mg/kg
Number of subjects: 20
Study: 31688884

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 517

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 517
Study: 28872484

Group type: EXPERIMENTAL
Intervention: Xenon anesthesia
Number of subjects: 492

Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 492

Group type: COMPARATOR
Intervention: Total intravenous anesthesia
Number of subjects: 492

Group type: COMPARATOR
Intervention: Xenon vs Sevoflurane
Number of subjects: 492
Study: 26599904

Group type: EXPERIMENTAL
Intervention: Icotinib (125 mg tablet, three times per day)
Number of subjects: 128
Study: 21853340

Group type: EXPERIMENTAL
Intervention: Incredible Years parenting programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost analysis of the Incredible Years programme
Number of subjects: 0
Study: 21216384

Group type: EXPERIMENTAL
Intervention: Reduced frequency Lissajous feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lissajous feedback (standard frequency)
Number of subjects: 0
Study: 18485269

Group type: EXPERIMENTAL
Intervention: Paper questionnaire using numerical rating scales
Number of subjects: 200

Group type: COMPARATOR
Intervention: Electronic questionnaire using visual analogue scales (with or without a numerical indicator)
Number of subjects: 200
Study: 22525343

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 24
Study: 15671570

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at 0.125 gm/m2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at 0.5 gm/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12858462

Group type: EXPERIMENTAL
Intervention: 20 micro g of teriparatide by daily self-injection
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: 40 micro g of teriparatide by daily self-injection
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 10206803

Group type: EXPERIMENTAL
Intervention: Perflenapent (EchoGen)
Number of subjects: 13
Study: 7753338

Group type: EXPERIMENTAL
Intervention: Corticotropin-releasing hormone (CRH) infusion (1 microgram/kg/h) with metyrapone
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: Metyrapone alone
Number of subjects: 6
Study: 2276652

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Terbutaline
Number of subjects: 30
Study: 7004845

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 138
Study: 30184222

Group type: EXPERIMENTAL
Intervention: Complementary food supplements (CFSs)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (child-feeding counseling for mothers)
Number of subjects: 25
Study: 27297847

Group type: EXPERIMENTAL
Intervention: Eliminating patient copayment for P2Y12 receptor inhibitor therapy
Number of subjects: 11000

Group type: COMPARATOR
Intervention: Control group (standard copayment)
Number of subjects: 11000
Study: 24685421

Group type: EXPERIMENTAL
Intervention: Offer of treatment by a homeopath
Number of subjects: 162

Group type: COMPARATOR
Intervention: No Offer
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 162
Study: 22425028

Group type: EXPERIMENTAL
Intervention: Multiple vendor-operated wireless POS terminals for 9 months (June 2008-February 2009)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single market-operated terminal
Number of subjects: 0
Study: 20056802

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18566455

Group type: EXPERIMENTAL
Intervention: ETDRS visual acuity measurements
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: ETDRS visual acuity measurements (revised)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Visual acuity at week 1 visit
Number of subjects: 107
Study: 17108494

Group type: EXPERIMENTAL
Intervention: ADL based rehabilitation (ABR) for 2 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Exercise based rehabilitation (EBR) for 4 weeks
Number of subjects: 13
Study: 14685447

Group type: EXPERIMENTAL
Intervention: Advice from a multiprofessional breastfeeding team (G1)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Advice from a pediatrician trained in breastfeeding (G2)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Advice from a pediatrician with no breastfeeding training (G3)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Use of a pacifier
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Maternal schooling
Number of subjects: 101
Study: 11076105

Group type: EXPERIMENTAL
Intervention: Dialysis vintage
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Calcium, phosphorus, and vintage (as predictors)
Number of subjects: 310
Study: 8980935

Group type: EXPERIMENTAL
Intervention: RAT2 (ranitidine 300 mg twice daily, amoxycillin 1000 mg twice daily, plus tinidazole 500 mg twice daily for 2 weeks)
Number of subjects: 232

Group type: COMPARATOR
Intervention: RA2 (ranitidine 300 mg twice daily plus amoxycillin 1000 mg twice daily for 2 weeks)
Number of subjects: 232
Study: 1727754

Group type: EXPERIMENTAL
Intervention: Tube-fed nutrition (1.5 g/kg protein and 167 kJ/kg daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Regular diet (control)
Number of subjects: 31
Study: 6748919

Group type: EXPERIMENTAL
Intervention: TMJ repositioning with a splint that optimized jaw position
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Placebo splint with no occlusal contact
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal condition (without a bite splint)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Splint that magnified the subjects normal degree of malocclusion
Number of subjects: 11
Study: 29976087

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29246659

Group type: EXPERIMENTAL
Intervention: AND exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 80
Study: 25967526

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004% preserved with SofZia (TRAVATAN Z solution)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Benzalkonium chloride‐preserved latanoprost 0.005% (XALATAN)
Number of subjects: 56
Study: 25303370

Group type: EXPERIMENTAL
Intervention: Patients with gastric tissue expressing IL-22
Number of subjects: 68

Group type: COMPARATOR
Intervention: Patients without gastric tissue expressing IL-22
Number of subjects: 68
Study: 21987393

Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (immediate-treatment group)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo (delayed-treatment group)
Number of subjects: 155
Study: 20022188

Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise training for 6 months
Number of subjects: 332

Group type: COMPARATOR
Intervention: Quartile 1 (referent group)
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Quartile 2
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Quartile 3
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Quartile 4
Number of subjects: 332
Study: 17873022

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion at a rate of 5 pmol/kg per minute for 180 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ghrelin infusion
Number of subjects: 15
Study: 16119352

Group type: EXPERIMENTAL
Intervention: Signal+masker trials
Number of subjects: 12

Group type: COMPARATOR
Intervention: Signal-alone trials
Number of subjects: 12
Study: 11840226

Group type: EXPERIMENTAL
Intervention: Sustained hypertension
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Borderline hypertension
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Normotensive
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Historical stroke and myocardial infarction
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Diabetes, uricaemia, and high heart rate
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Pulse blood pressure and murmurs at the neck
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Historical heart failure, proteinuria, and tachycardia
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Historical stroke and myocardial infarction, pulmonary disease, left ventricular hypertrophy, diabetes, and uricaemia
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Hypercholesterolaemia
Number of subjects: 3282
Study: 10512130

Group type: EXPERIMENTAL
Intervention: Paclitaxel (60 mg/m2) given as a 3‐h infusion on days 1, 8, 15, 22, 29 and 36; CHART started on day 15 with 150 cGy/fraction given three times a day for a total dose of 54 Gy in 12 days.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Paclitaxel and CHART regimen
Number of subjects: 20
Study: 7555483

Group type: EXPERIMENTAL
Intervention: Programmable implantable pump therapy
Number of subjects: 224
Study: 2252119

Group type: EXPERIMENTAL
Intervention: Open diagnostic peritoneal lavage
Number of subjects: 242

Group type: COMPARATOR
Intervention: Closed diagnostic peritoneal lavage
Number of subjects: 242
Study: 6113885

Group type: EXPERIMENTAL
Intervention: Fazadinium bromide 1 mg . kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fazadinium bromide 1.5 mg . kg‐1
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fazadinium bromide
Number of subjects: 50
Study: 31028768

Group type: EXPERIMENTAL
Intervention: Primary selective laser trabeculoplasty (SLT)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 355
Study: 30243214

Group type: EXPERIMENTAL
Intervention: 4-hour instructor-led ICF training
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study: 26808988

Group type: EXPERIMENTAL
Intervention: Left atrial (LA) enlargement in female AF patients
Number of subjects: 2615

Group type: EXPERIMENTAL
Intervention: Left atrial (LA) diameter
Number of subjects: 2615
Study: 24477763

Group type: EXPERIMENTAL
Intervention: no-stop signal bias
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: stop-signal bias
Number of subjects: 18

Group type: COMPARATOR
Intervention: no-stop trials
Number of subjects: 18
Study: 23176536

Group type: EXPERIMENTAL
Intervention: E-ADL-Test
Number of subjects: 139
Study: 20236365

Group type: EXPERIMENTAL
Intervention: Uridine (36 g tid on 10 consecutive days per month; n=10)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg nocte; n=12)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Uridine plus Pravastatin (n=11)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Neither (Control group; n=12)
Number of subjects: 45
Study: 17401044

Group type: EXPERIMENTAL
Intervention: 0.25 mg dexamethasone suppression test
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 32
Study: 15707766

Group type: EXPERIMENTAL
Intervention: Saffron 30 mg/day (BD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day (BD)
Number of subjects: 40
Study: 12123331

Group type: EXPERIMENTAL
Intervention: IRIFAFU (Irinotecan 200 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 850 mg/m2)
Number of subjects: 234

Group type: COMPARATOR
Intervention: MTXFAFU (Methotrexate 750 mg/m2 + Levo-FA 250 mg/m2 + 5-FU 800 mg/m2)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: IRIFAFU
Number of subjects: 234

Group type: COMPARATOR
Intervention: MTXFAFU
Number of subjects: 234
Study: 10407253

Group type: COMPARATOR
Intervention: Immunostimulant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfusions of plasma rich in anti-HIV1
Number of subjects: 0
Study: 8569016

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: E+P regimens (0.625 mg/d of CEE plus 10 mg/d of MPA for the first 12 days, 0.625 mg/d of CEE plus 2.5 mg/d of MPA, or 0.625 mg/d of CEE plus 200 mg/d of MP for the first 12 days)
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of CEE
Number of subjects: 596

Group type: EXPERIMENTAL
Intervention: E+P regimens
Number of subjects: 596
Study: 2013416

Group type: EXPERIMENTAL
Intervention: Big gulps
Number of subjects: 14

Group type: COMPARATOR
Intervention: Little swallows
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Wet swallows (patients)
Number of subjects: 14
Study: 6122852

Group type: EXPERIMENTAL
Intervention: 2% phenoxetol and 0.2% chlorhexidine cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30014302

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 42

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 42
Study: 26375410

Group type: EXPERIMENTAL
Intervention: Weight loss diet (D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight loss diet combined with supervised exercise training (D + E)
Number of subjects: 0
Study: 25481936

Group type: EXPERIMENTAL
Intervention: Early-start AET program
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early-start AET protocol (TR)
Number of subjects: 200
Study: 22403594

Group type: EXPERIMENTAL
Intervention: Additional training unit (conducting anamnesis and clinical examination) before OSCE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study: 19382041

Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pancreaticojejunostomy
Number of subjects: 0
Study: 17559733

Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg once-daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg once-daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once-daily
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg twice-daily
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 16354865

Group type: EXPERIMENTAL
Intervention: Disease Management Program (DMP)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Control group (no DMP)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Caregivers of patients residing in an institution
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Caregivers overall
Number of subjects: 290
Study: 11778705

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 20
Study: 11207490

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 400 micrograms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous syntocinon 10 IU
Number of subjects: 60
Study: 9766535

Group type: EXPERIMENTAL
Intervention: Methohexital
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70
Study: 7828614

Group type: EXPERIMENTAL
Intervention: PET (FDG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SPET (HMPAO)
Number of subjects: 45
Study: 3396568

Group type: EXPERIMENTAL
Intervention: High fat, high protein diet (FP)
Number of subjects: 5

Group type: COMPARATOR
Intervention: High carbohydrate diet (CHO)
Number of subjects: 5
Study: 8042809

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (360 micrograms)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inhaled ipratropium bromide (72 micrograms)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol and ipratropium bromide
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Bronchodilator treatment
Number of subjects: 42
Study: 715126

Group type: EXPERIMENTAL
Intervention: Overhabituation exposure conditions (60, 120, or 180 trials) with standard stimulus (SS)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Auditory stimulus intensities (60 or 85 dB)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group defined by numerous overhabituation responses
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Length of overhabituation
Number of subjects: 108
Study: 30591006

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 29879285

Group type: EXPERIMENTAL
Intervention: Dorsal hump reduction simulation
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Combined simulation of dorsum and tip rotation
Number of subjects: 813

Group type: COMPARATOR
Intervention: Tip rotation alone
Number of subjects: 813
Study: 27775977

Group type: EXPERIMENTAL
Intervention: Isostearamidopropyl morpholine lactate (0.5% and 1.0% aq)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Oleamidopropyl dimethylamine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dimethylaminopropylamine
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cocamide diethanolamine (DEA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Co-reactivity among surfactants
Number of subjects: 47
Study: 24767263

Group type: EXPERIMENTAL
Intervention: Emotional Freedom Techniques (EFT)
Number of subjects: 59
Study: 23181415

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise program (8 supervised sessions, 6 exercises at home, at least 3 times per week for 12 weeks)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no neuromuscular training program)
Number of subjects: 62
Study: 21067350

Group type: EXPERIMENTAL
Intervention: ceftaroline 600 mg every 12 h for 5-7 days
Number of subjects: 1228

Group type: COMPARATOR
Intervention: ceftriaxone 1 g every 24 h for 5-7 days
Number of subjects: 1228
Study: 17363037

Group type: EXPERIMENTAL
Intervention: Lead exposure (blood lead concentrations)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Neurobehavioral measures and IQ
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Low-level lead exposure
Number of subjects: 507
Study: 15971717

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12394436

Group type: EXPERIMENTAL
Intervention: Stapled rectal mucosectomy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Closed hemorrhoidectomy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 10023786

Group type: EXPERIMENTAL
Intervention: Predischarge apnea assessment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Predischarge apnea assessment in infants with grade 3 or 4 intraventricular hemorrhage
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Predischarge apnea assessment in infants without grade 3 or 4 intraventricular hemorrhage
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Predischarge respiratory recordings
Number of subjects: 164
Study: 7548903

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rifampicin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both rifabutin and rifampicin
Number of subjects: 50
Study: 2247767

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (conventional antihypertensive treatment)
Number of subjects: 59
Study: 30074437

Group type: EXPERIMENTAL
Intervention: Behaviour change interventions
Number of subjects: 118

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 118
Study: 28605207

Group type: EXPERIMENTAL
Intervention: Pain Neurophysiology Education (PNE) treatment
Number of subjects: 39
Study: 26842122

Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO-stress) infusion
Number of subjects: 331

Group type: COMPARATOR
Intervention: Right atrial pacing
Number of subjects: 331
Study: 24628577

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS)
Number of subjects: 300
Study: 21848848

Group type: EXPERIMENTAL
Intervention: Diet with 25% inclusion level of OPF (HAF)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diet with 50% inclusion of OPF
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100% concentrate control diet (CON)
Number of subjects: 24
Study: 19647866

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg oral twice daily)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Efavirenz (600 mg oral once daily)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 566

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Raltegravir and Efavirenz
Number of subjects: 566
Study: 17890274

Group type: EXPERIMENTAL
Intervention: Corticosteroid injections
Number of subjects: 383

Group type: COMPARATOR
Intervention: Wait-and-see policy
Number of subjects: 383

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 383